BLS Pharmaceuticals has opened FY27 with record quarterly revenue, positive operating cash flow and reaffirmed full-year guidance. The report contains conflicting Q1 revenue figures of $26.7 million and $27.5 million, while its Scotland expansion remains subject to regulatory approval.
- Record Q1 FY27 revenue reported at either $26.7 million or $27.5 million
- $2.0 million positive operating cash flow and $12.7 million closing cash
- FY27 guidance reaffirmed at $105 million to $115 million revenue
- Scotland GMP facility ready for inspection and licensing, subject to approvals
- New referral and commercialisation relationships broaden the pharmaceutical pipeline
Record quarter opens FY27, but revenue figure conflicts
BLS Pharmaceuticals Limited (ASX:BLS) has started FY27 with its strongest quarterly revenue on record, although the company’s own report gives two different figures for the result. The headline and key financial summary state revenue of $26.7 million, up 23% on Q4 FY26, while the body describes revenue of $27.5 million, up 27% on the June quarter. BLS does not explain the discrepancy.
Whichever figure is used, the company reported a substantial quarter driven by higher manufacturing volumes in Australia, growth in white-label and contract manufacturing, and continued supply to ADREXpharma in Germany. The German relationship sits within the $50 million German supply agreement, a two-year contract with a minimum purchase commitment of $25 million in its first 12 months.
Positive cash flow continues alongside expansion spending
Customer cash receipts rose to $22.4 million from $20.7 million in the previous quarter, while net cash from operating activities was $2.0 million. That was below the $6.3 million generated in Q4 FY26, but left BLS operating cash-flow positive as it continued investing in manufacturing capacity.
Cash and cash equivalents fell modestly to $12.7 million at 30 September from $13.3 million three months earlier. Investing cash outflows totalled $2.7 million, including $2.4 million for the Scotland facility and $0.3 million for Australian expansion. The Appendix 4C also records $1.5 million drawn across two loan facilities, with a separate $3.0 million Westpac overdraft facility listed as undrawn.
Guidance depends on capacity, contracts and new customers
BLS reaffirmed FY27 revenue guidance of $105 million to $115 million and an adjusted EBITDA margin of 23% to 26%. The revenue range implies growth of approximately 42% to 55% on FY26 revenue of $74.2 million, according to the company.
The company says delivery will depend on higher utilisation of its Australian manufacturing capacity, continued execution of international supply agreements, additional pharmaceutical manufacturing customers and increasing international manufacturing activity. Its Brisbane GMP facility has estimated annual revenue capacity of more than $250 million, although the report does not quantify current utilisation.
Scotland facility reaches inspection stage
Construction and equipment installation at BLS’s Scottish Borders GMP facility continued during the quarter. Chief executive Sam Watson said the facility was complete and ready for inspection and licensing, but the site remains subject to the required regulatory approvals before it can begin operations.
BLS also added commercial channels during the period. Cayman Chemical entered a referral agreement with a BLS subsidiary for prospective customers seeking finished psilocybin and MDMA dosage forms, while a non-binding heads of agreement with Trexapharm could make BLS its preferred Australian commercial partner for TREXAVIVE®. Both arrangements create potential manufacturing or supply opportunities; neither is presented as guaranteed revenue in the report.
Execution now matters more than the record headline
The quarter gives BLS a strong starting point, with positive operating cash flow and guidance intact. But the conflicting revenue disclosure needs clarification, particularly because the difference changes the implied quarter-on-quarter growth rate. The next evidence will come from how quickly the German contract converts into receipts, whether new relationships generate orders, and whether Scotland moves from construction into licensed production.
Bottom Line?
BLS has momentum and cash-generating operations, but the revenue discrepancy and Scotland’s approval timetable are the immediate points requiring resolution.
Questions in the middle?
- Which Q1 revenue figure will BLS confirm: $26.7 million or $27.5 million?
- When will the Scottish facility complete inspection and licensing, and when could production begin?
- How much revenue will come from Cayman Chemical referrals, Trexapharm and additional pharmaceutical customers during FY27?